Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by specific organ manifestations and the production of autoantibodies to nuclear antigens. SLE can induce severe organ damage and carries the risk of fatal outcome. During recent years, no major progress has been made regarding new treatment options except for the introduction of mycophenolate mofetil. Therefore, the results of several large clinical trials using biological agents for treatment of SLE were hopefully awaited. Yet, the application of abatacept, belimumab and rituximab, respectively, to non-renal or renal lupus patients surprisingly has not been successful. Other studies using different agents have not been completed yet. Nevertheless, the results available so far will have a significant impact on the design of future clinical trials and will stimulate the debate on new targets for treatment of SLE.
Keywords: Systemic lupus erythematosus, biologics, clinical trials
Current Drug Discovery Technologies
Title: Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Volume: 6 Issue: 4
Author(s): Johann O. Schroder and Rainald A. Zeuner
Affiliation:
Keywords: Systemic lupus erythematosus, biologics, clinical trials
Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by specific organ manifestations and the production of autoantibodies to nuclear antigens. SLE can induce severe organ damage and carries the risk of fatal outcome. During recent years, no major progress has been made regarding new treatment options except for the introduction of mycophenolate mofetil. Therefore, the results of several large clinical trials using biological agents for treatment of SLE were hopefully awaited. Yet, the application of abatacept, belimumab and rituximab, respectively, to non-renal or renal lupus patients surprisingly has not been successful. Other studies using different agents have not been completed yet. Nevertheless, the results available so far will have a significant impact on the design of future clinical trials and will stimulate the debate on new targets for treatment of SLE.
Export Options
About this article
Cite this article as:
Schroder O. Johann and Zeuner A. Rainald, Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869010
DOI https://dx.doi.org/10.2174/157016309789869010 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nucleic Acids Modulate Autoimmunity Through Nucleic-Acid-Specific Toll-Like Receptors
Current Medicinal Chemistry Natural Killer T Cells and Autoimmune Disease
Current Molecular Medicine The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Allosteric Regulators of the Proteasome: Potential Drugs and a Novel Approach for Drug Design
Current Medicinal Chemistry Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine The Medical Functions of Probiotics and Their Role in Clinical Nutrition
Current Nutrition & Food Science The Emergence of Multiplexed Technologies as Diagnostic Platforms in Systemic Autoimmune Diseases
Current Medicinal Chemistry MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Synthesis and Evaluation of Cytotoxicity and Inhibitory Effect on Nitric Oxide Production by J774A.1 Macrophages of New Anthraquinone Derivatives
Medicinal Chemistry A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Polypeptide Delivery Across The Blood-Brain Barrier
Current Drug Targets - CNS & Neurological Disorders Immune Modulation by Plasmid DNA-mediated Cytokine Gene Transfer
Current Pharmaceutical Design The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Peptide Arrays for the Analysis of Antibody Epitope Recognition Patterns
Mini-Reviews in Organic Chemistry Toll-Like Receptor Signaling Mechanisms Involved in Dendritic Cell Activation: Potential Therapeutic Control of T Cell Polarization
Current Pharmaceutical Design The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets